The cost-effectiveness of the early insulin use treatment pathway in the ADA/EASD joint consensus algorithm for the treatment of type 2 diabetes (T2D)

被引：0
|
作者：
Willis, Michael
Asseburg, Christian
Neslu-San, Cheryl
Persson, Ulf
机构：
来源：
DIABETES | 2008年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A98 / A98
页数：1
相关论文
共 50 条
  • [1] Cost-Effectiveness of Insulin Icodec for the Treatment of Type 2 Diabetes (T2D) in Canada
    Garcia, David A.
    Mau, Godfrey
    Vuong, Vivian
    Singh, Sumeet
    Jensen, Morten S.
    Goldenberg, Ronald
    [J]. DIABETES, 2024, 73
  • [2] Cost-effectiveness of treatment of type 2 diabetes
    Eastman, RC
    [J]. DIABETES CARE, 1998, 21 (03) : 464 - 465
  • [3] Practical implementation of ADA/EASD consensus algorithm in patients with type 2 diabetes in Pakistan
    Hasan, Muhammad Imtiaz
    Amer, Wasim
    Junaid, Nabeea
    [J]. JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION, 2018, 68 (09) : 1304 - 1309
  • [4] THE COST-EFFECTIVENESS OF DAPAGLIFLOZIN IN COMBINATION WITH INSULIN FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN SPAIN
    Sanchez-Covisa, J.
    Capel, M.
    Schmidt, R.
    Charokopou, M.
    Verheggen, B. G.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A350 - A350
  • [5] COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN IN THE TREATMENT OF T2D WITH PREVIOUS CARDIOVASCULAR DISEASE IN ITALY
    Iannazzo, S.
    Mannucci, E.
    Reifsnider, O.
    Maggioni, A. P.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A480 - A480
  • [6] COST-EFFECTIVENESS OF DAPAGLIFLOZIN AS ADD-ON TO INSULIN FOR THE TREATMENT OF TYPE 2 DIABETES IN THE NETHERLANDS
    van Haalen, H. G. M.
    Pompen, M.
    Bergenheim, K.
    McEwan, P.
    Townsend, R.
    Roudaut, M.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A441 - A441
  • [7] Mood and cognitive effects of insulin treatment (Tx) in type 2 diabetes (T2D) patients
    Cox, Daniel J.
    Mccall, Anthony
    Kovatchev, Boris
    Ilag, Liza L.
    Sarwat, Samiha
    Tan, Meng H.
    [J]. DIABETES, 2007, 56 : A496 - A496
  • [8] Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 2 diabetes in the UK
    McEwan, Phil
    Poole, Chris D.
    Tetlow, Tony
    Holmes, Paul
    Currie, Craig J.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 : S21 - S31
  • [9] THE COST-EFFECTIVENESS OF SAXAGLIPTIN VERSUS NPH INSULIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN POLAND
    Kolasa, K.
    Niewada, M.
    de Troconiz, J. Puelles Fernandez
    Townsend, R.
    McEwan, P.
    [J]. VALUE IN HEALTH, 2010, 13 (07) : A290 - A290
  • [10] An Early Assessment of the Real-World Treatment Patterns of Type 2 Diabetes: A Comparison to the 2018 ADA/EASD Consensus Report Recommendations
    Jay P. Bae
    Zbigniew A. Kadziola
    Dongju Liu
    Chanadda Chinthammit
    Kristina S. Boye
    Kieren J. Mather
    [J]. Diabetes Therapy, 2022, 13 : 1499 - 1510
12345